New pill offers hope for patients with stubborn blood-destroying disease

NCT ID NCT07453368

First seen Mar 07, 2026 · Last updated May 14, 2026 · Updated 12 times

Summary

This study tests a daily oral drug called orelabrutinib in 50 adults with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. The goal is to see if the drug can control the disease by stopping the immune system from destroying red blood cells. Participants will take the pill for at least 12 weeks, and those who respond may continue for up to a year or longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.